Actuate Therapeutics Inc (ACTU) NASDAQ
2.15
-0.12(-5.29%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.15
-0.12(-5.29%)
Currency In USD
Address
1751 River Run
Fort Worth, TX 76107
United States of America (the)
Phone
817 887 8455
Sector
Healthcare
Industry
Biotechnology
Employees
10
First IPO Date
August 13, 2024
| Name | Title | Pay | Year Born |
| Daniel Schmitt | Chief Executive Officer, President & Director | 600,000 | 1962 |
| Paul J. Lytle | Chief Financial Officer | 411,627 | 1968 |
| Andrew Mazar | Co-Founder & Chief Operating Officer | 675,000 | 1962 |
| Alan Kozikowski | Scientific Founder and Advisor | 0 | 1951 |
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.